Correspondence
LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs
N Engl J Med 2006; 354:422-423January 26, 2006
- Article
To the Editor:
Parkinson's disease is characterized by resting tremor, rigidity, and bradykinesia caused by the loss of dopaminergic neurons in the substantia nigra, a good response to levodopa, and the presence of Lewy bodies. The recently identified G2019S mutation in exon 41 of the leucine-rich repeat kinase 2 gene (LRRK2) accounts for 2 to 6 percent of familial and 1 to 2 percent of sporadic cases.1 The mutation is less common in Asian populations1 but prevalent in patients from North Africa who have Parkinson's disease, as we describe here.
We obtained blood samples from 104 unrelated index patients with Parkinson's disease (76 Arabs, 18 Europeans born in North Africa, 6 Sephardic Jews, and 4 black Africans) and sequenced exon 41 (see the Supplementary Appendix, available with the full text of this letter at www.nejm.org). Seventeen North African families with Parkinson's disease had been reported2; 87 index cases were new. The data for 151 healthy unrelated Arab controls, who were spouses of patients with neurologic disease, were also analyzed.
In the newly ascertained series of North African Arabs, 23 of 59 patients with Parkinson's disease were carriers of the G2019S mutation (39 percent), as compared with only 2 of 69 controls (3 percent; P<0.001) (Table 1Table 1
Frequency of the G2019S Mutation in North African Arabs with Familial and Sporadic Parkinson's Disease and in Ethnically Matched Controls.). In the previous study2 and the present study combined, 31 of the 104 probands (30 percent) were heterozygous (28 patients) or homozygous (3 patients) for the G2019S mutation. All but one of the 31 G2019S carriers were Arab (30 of 76; 39 percent); one was a Sephardic Jew. The frequency of the mutation among Arabs was 37 percent (10 of 27; 95 percent confidence interval, 22.4 to 61.2 percent) in familial cases and 41 percent (20 of 49; 95 percent confidence interval, 28.8 to 57.8 percent) in sporadic cases. In four families, the mutation was present in two additional patients and in three of nine unaffected relatives, who were 29, 32, and 43 years of age. It was also present in 2 of 151 North African controls, who were 22 and 58 years of age. All carriers had genotypes consistent with a common haplotype3 spanning 60 kb (see the Supplementary Appendix).The 33 G2019S carriers (including the 2 additional patients) and the 73 noncarriers had similar ages at the onset of disease and at examination (see the table in the Supplementary Appendix for these details and other clinical details about the patients). The symptoms of two homozygous carriers from Algeria and one from Morocco began at the age of 54, 56, and 62 years, respectively, and were typical of Parkinson's disease. One carrier of the LRRK2 G2019S mutation also had a heterozygous A398T parkin mutation, and another had a homozygous triplication in exon 2 of parkin, suggesting digenic inheritance. The latter had the earliest age at onset (31 years) but also the typical levodopa-responsive parkinsonism expected in patients with parkin mutations.4
Our preliminary2 and present results show that the frequency of the G2019S mutation is strikingly high among North African Arabs with familial Parkinson's disease (37 percent; 95 percent confidence interval, 22.4 to 61.2 percent) and more unexpectedly, in those without a family history of the disease (41 percent; 95 percent confidence interval, 28.8 to 57.8 percent). Although it is present at a low level in Arab controls, the G2019S mutation nevertheless constitutes a significant risk factor for Parkinson's disease in this population (odds ratio, 48.6; 95 percent confidence interval, 11.2 to 211.0, for combined familial and sporadic cases).
The high frequency of a dominant mutation in apparently sporadic cases of Parkinson's disease cannot be explained by recurrent events, since the mutation is associated with the same ancestral haplotype in several populations.3,5 Reduced penetrance (85 percent at 70 years of age among whites,5 but not yet analyzed among Arabs) may account for some apparently sporadic cases. A censor effect may account for others, since in 11 of 17 cases, at least one parent died before 65 years of age.
The phenotype of the G2019S carriers was similar to that of other persons with Parkinson's disease; we could not distinguish one from the other. Our data suggest, however, that more severe progression and more cognitive changes occur in carriers than in noncarriers. Interestingly, homozygous carriers could not be distinguished from heterozygous carriers, and their mean age at onset was even later, indicating the absence of a dose effect, as observed in other studies.1 This result is consistent with an increase in kinase activity caused by the G2019S mutation.6 Possible digenic inheritance in two patients with mutations in both parkin and LRRK2 did not seem to cause a more severe phenotype, either,7 but the earliest onset was observed in the patient with LRRK2 who also carried a homozygous parkin mutation, suggesting an additive effect.
The prevalence of the G2019S mutation is also high in Ashkenazi Jews with Parkinson's disease, reaching 29.7 percent in familial cases and 13.3 percent in sporadic cases.8 Our finding has consequences for genetic diagnosis and counseling, although penetrance must be better evaluated in North African Arabs and Ashkenazi Jews for an optimal evaluation of risk.
Suzanne Lesage, Ph.D.
Alexandra Dürr, M.D., Ph.D.
INSERM Unité 679, 75651 Paris CEDEX 13, FranceMeriem Tazir, M.D.
Centre Hospitalier Universitaire (CHU) Mustapha, 16000 Algiers, AlgeriaEbba Lohmann, M.D.
Anne-Louise Leutenegger, Ph.D.
Sabine Janin, B.S.
INSERM Unité 679, 75651 Paris CEDEX 13, FrancePierre Pollak, M.D.
CHU de Grenoble, 38000 Grenoble, FranceAlexis Brice, M.D.
INSERM Unité 679, 75651 Paris CEDEX 13, France
brice@ccr.jussieu. fr for the French Parkinson's Disease Genetics Study Group
Dr. Pollak reports having received consulting fees from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and Valeant and lecture fees from Medtronic, GlaxoSmithKline, and Boehringer Ingelheim; and Dr. Brice, lecture fees from GlaxoSmithKline.
8 References1
Brice A . Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128:2760-2762
CrossRef | Web of Science | Medline2
Lesage S ,Ibanez P ,Lohmann E , et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-787
CrossRef | Web of Science | Medline3
Lesage S ,Leutenegger AL ,Ibanez P , et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005;77:330-332
CrossRef | Web of Science | Medline4
Lucking CB ,Durr A ,Bonifati V , et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567
Full Text | Web of Science | Medline5
Kachergus J ,Mata IF ,Hulihan M , et al. Identification of a novel LRRK2 mutation linked to autosomal dominant Parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680
CrossRef | Web of Science | Medline6
West AB ,Moore DJ ,Biskup S . Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005;102:16842-16847
CrossRef | Web of Science | Medline7
Paisan-Ruiz C ,Lang AE ,Kawarai T , et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 2005;65:696-700
CrossRef | Web of Science | Medline8
Ozelius L ,Senthil G ,Saunders-Pullman R , et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425
Full Text | Web of Science | Medline
- Citing Articles (178)
Citing Articles
1
Matthew B. Stern, Anthony Lang, Werner Poewe. (2012) Toward a redefinition of Parkinson's disease. Movement Disorders 27:1, 54-60
CrossRef2
Markos Poulopoulos, Etty Cortes, Jean-Paul G. Vonsattel, Stanley Fahn, Cheryl Waters, Lucien J. Cote, Carol Moskowitz, Lawrence S. Honig, Lorraine N. Clark, Karen S. Marder, Roy N. Alcalay. (2011) Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD. Journal of Molecular Neuroscience
CrossRef3
K. Löw, P. Aebischer. (2011) Use of viral vectors to create animal models for Parkinson's disease. Neurobiology of Disease
CrossRef4
Claire Henchcliffe, Richard Dodel, M. Flint Beal. (2011) Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology 95:4, 601-613
CrossRef5
David Crosiers, Jessie Theuns, Patrick Cras, Christine Van Broeckhoven. (2011) Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy 42:2, 131-141
CrossRef6
Jason P. Covy, Benoit I. Giasson. (2011) α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease. NeuroToxicology 32:5, 622-629
CrossRef7
Owen A Ross, Alexandra I Soto-Ortolaza, Michael G Heckman, Jan O Aasly, Nadine Abahuni, Grazia Annesi, Justin A Bacon, Soraya Bardien, Maria Bozi, Alexis Brice, Laura Brighina, Christine Van Broeckhoven, Jonathan Carr, Marie-Christine Chartier-Harlin, Efthimios Dardiotis, Dennis W Dickson, Nancy N Diehl, Alexis Elbaz, Carlo Ferrarese, Alessandro Ferraris, Brian Fiske, J Mark Gibson, Rachel Gibson, Georgios M Hadjigeorgiou, Nobutaka Hattori, John PA Ioannidis, Barbara Jasinska-Myga, Beom S Jeon, Yun Joong Kim, Christine Klein, Rejko Kruger, Elli Kyratzi, Suzanne Lesage, Chin-Hsien Lin, Timothy Lynch, Demetrius M Maraganore, George D Mellick, Eugénie Mutez, Christer Nilsson, Grzegorz Opala, Sung Sup Park, Andreas Puschmann, Aldo Quattrone, Manu Sharma, Peter A Silburn, Young Ho Sohn, Leonidas Stefanis, Vera Tadic, Jessie Theuns, Hiroyuki Tomiyama, Ryan J Uitti, Enza Maria Valente, Simone van de Loo, Demetrios K Vassilatis, Carles Vilariño-Güell, Linda R White, Karin Wirdefeldt, Zbigniew K Wszolek, Ruey-Meei Wu, Matthew J Farrer. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study. The Lancet Neurology 10:10, 898-908
CrossRef8
Azad Kumar, Mark R. Cookson. (2011) Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Reviews in Molecular Medicine 13,
CrossRef9
Karin Wirdefeldt, Margaret Gatz, Chandra A. Reynolds, Carol A. Prescott, Nancy L. Pedersen. (2011) Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiology of Aging 32:10, 1923.e1-1923.e8
CrossRef10
Teresa Botta-Orfila, Eduard Tolosa, Ellen Gelpi, Alex Sànchez-Pla, Maria-José Martí, Francesc Valldeoriola, Manel Fernández, Francesc Carmona, Mario Ezquerra. (2011) Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease. Neurobiology of Disease
CrossRef11
Jia Liu, Yongtao Zhou, Chaodong Wang, Tao Wang, Zheng Zheng, Piu Chan. (2011) Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Parkinsonism & Related Disorders
CrossRef12
Chin-Hsien Lin, Pei-I Tsai, Ruey-Meei Wu, Cheng-Ting Chien. (2011) LRRK2 Parkinson’s disease: from animal models to cellular mechanisms. Reviews in the Neurosciences 22:4, 411-418
CrossRef13
Soraya Bardien, Suzanne Lesage, Alexis Brice, Jonathan Carr. (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism & Related Disorders 17:7, 501-508
CrossRef14
J. William Langston. 2011. The Emerging Entity of Pre-Motor Parkinson's Disease. , 93-104.
CrossRef15
C. Warren Olanow, Anthony E. Lang. 2011. Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease. , 455-461.
CrossRef16
Doaa I. Hashad, Abla A. Abou-Zeid, Ghada A. Achmawy, Horeya M.O. Saad Allah, Marwa A. Saad. (2011) G2019S Mutation of the Leucine-Rich Repeat Kinase 2 Gene in a Cohort of Egyptian Patients with Parkinson's Disease. Genetic Testing and Molecular Biomarkers110623105611003
CrossRef17
Hui-Ming Gao, Jau-Shyong Hong. (2011) Gene–environment interactions: Key to unraveling the mystery of Parkinson's disease. Progress in Neurobiology 94:1, 1-19
CrossRef18
Karin Wirdefeldt, Hans-Olov Adami, Philip Cole, Dimitrios Trichopoulos, Jack Mandel. (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. European Journal of Epidemiology 26:S1, 1-58
CrossRef19
Ling-yan Yao, Ji-feng Guo, Lei Wang, Ren-he Yu, Qi-ying Sun, Qian Pan, Kun Xia, Bei-sha Tang, Lu Shen. (2011) LRRK2 Pro755Leu variant in ethnic Chinese population with Parkinson's disease. Neuroscience Letters 495:1, 35-38
CrossRef20
Thomas Gasser, John Hardy, Yoshikuni Mizuno. (2011) Milestones in PD genetics. Movement Disorders 26:6, 1042-1048
CrossRef21
2011. Bibliography. , 207-222.
CrossRef22
Gregor Kuhlenbäumer, Julia Hullmann, Silke Appenzeller. (2011) Novel genomic techniques open new avenues in the analysis of monogenic disorders. Human Mutation 32:2, 144-151
CrossRef23
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Current concepts on the etiology and pathogenesis of Parkinson disease. , 93-118.
CrossRef24
Oswaldo Lorenzo-Betancor, Lluís Samaranch, Mario Ezquerra, Eduardo Tolosa, Elena Lorenzo, Jaione Irigoyen, Carles Gaig, María A. Pastor, Alexandra I. Soto-Ortolaza, Owen A. Ross, María C. Rodríguez-Oroz, Francesc Valldeoriola, María J. Martí, María R. Luquin, Jordi Perez-Tur, Juan A. Burguera, José A. Obeso, Pau Pastor. (2011) LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Movement Disordersn/a-n/a
CrossRef25
Ji Sun Kim, Jin Whan Cho, Hyeeun Shin, Won Yong Lee, Chang-Seok Ki, Ah Ra Cho, Hee-Tae Kim. (2011) A Korean Parkinson's disease family with the LRRK2 p.Tyr1699Cys mutation showing clinical heterogeneity. Movement Disordersn/a-n/a
CrossRef26
Soreya Belarbi, Nassima Hecham, Suzanne Lesage, Mohamed I. Kediha, Nourredine Smail, Traki Benhassine, Farida Ysmail-Dahlouk, Ebba Lohman, Badia Benhabyles, Tarik Hamadouche, Salima Assami, Alexis Brice, Meriem Tazir. (2010) LRRK2 G2019S mutation in Parkinson’s disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism & Related Disorders 16:10, 676-679
CrossRef27
Kumar M Prakash, Eng-King Tan. (2010) Development of Parkinson’s disease biomarkers. Expert Review of Neurotherapeutics 10:12, 1811-1825
CrossRef28
Petra Yescas, Marisol López, Nancy Monroy, Marie-Catherine Boll, Mayela Rodríguez-Violante, Ulises Rodríguez, Adriana Ochoa, María Elisa Alonso. (2010) Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Neuroscience Letters 485:2, 79-82
CrossRef29
Marta San Luciano, Richard B. Lipton, Cuiling Wang, Mindy Katz, Molly E. Zimmerman, Amy E. Sanders, Laurie J. Ozelius, Susan B. Bressman, Rachel Saunders-Pullman. (2010) Clinical expression of LRRK2 G2019S mutations in the elderly. Movement Disorders 25:15, 2571-2576
CrossRef30
Barbara Jasinska-Myga, Jennifer Kachergus, Carles Vilariño-Güell, Christian Wider, Alexandra I. Soto-Ortolaza, Mounir Kefi, Lefkos T. Middleton, Lianna Ishihara-Paul, Rachel A. Gibson, Rim Amouri, Samia Ben Yahmed, Samia Ben Sassi, Mourad Zouari, Ghada El Euch, Owen A. Ross, Faycal Hentati, Matthew J. Farrer. (2010) Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa. Movement Disorders 25:13, 2052-2058
CrossRef31
Yoshihiro Miyake, Yoshio Tsuboi, Midori Koyanagi, Takahiro Fujimoto, Senji Shirasawa, Chikako Kiyohara, Keiko Tanaka, Wakaba Fukushima, Satoshi Sasaki, Tatsuo Yamada, Tomoko Oeda, Takami Miki, Nobutoshi Kawamura, Nobutaka Sakae, Hidenao Fukuyama, Yoshio Hirota, Masaki Nagai. (2010) LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: A case–control study in Japan. Journal of the Neurological Sciences 297:1-2, 15-18
CrossRef32
Jason P. Covy, Benoit I. Giasson. (2010) The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. Journal of Neurochemistry 115:1, 36-46
CrossRef33
Jaya Sanyal, Biswanath Sarkar, Sabyasachi Ojha, Tapas Kumar Banerjee, Bidhan Chandra Ray, Vadlam Raghavendra Rao. (2010) Absence of Commonly Reported Leucine-Rich Repeat Kinase 2 Mutations in Eastern Indian Parkinson's Disease Patients. Genetic Testing and Molecular Biomarkers 14:5, 691-694
CrossRef34
John Hardy. (2010) Genetic Analysis of Pathways to Parkinson Disease. Neuron 68:2, 201-206
CrossRef35
Surendra S. Ambegaokar, Bidisha Roy, George R. Jackson. (2010) Neurodegenerative models in Drosophila: Polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiology of Disease 40:1, 29-39
CrossRef36
Owen A. Ross, Greggory J. Wilhoite, Justin A. Bacon, Alexandra Soto-Ortolaza, Jennifer Kachergus, Stephanie A. Cobb, Andreas Puschmann, Carles Vilariño-Güell, Matthew J. Farrer, Neill Graff-Radford, James F. Meschia, Zbigniew K. Wszolek. (2010) LRRK2 variation and Parkinson's disease in African Americans. Movement Disorders 25:12, 1973-1976
CrossRef37
Krisztina K. Johansen, Kåre Hasselberg, Linda R. White, Matthew J. Farrer, Jan O. Aasly. (2010) Genealogical studies in LRRK2-associated Parkinson’s disease in central Norway. Parkinsonism & Related Disorders 16:8, 527-530
CrossRef38
Jérémie Vitte, Sabine Traver, André Maués De Paula, Suzanne Lesage, Giorgio Rovelli, Olga Corti, Charles Duyckaerts, Alexis Brice. (2010) Leucine-Rich Repeat Kinase 2 Is Associated With the Endoplasmic Reticulum in Dopaminergic Neurons and Accumulates in the Core of Lewy Bodies in Parkinson Disease. Journal of Neuropathology and Experimental Neurology 69:9, 959-972
CrossRef39
Sonia Gandhi, Nicholas W Wood. (2010) Genome-wide association studies: the key to unlocking neurodegeneration?. Nature Neuroscience 13:7, 789-794
CrossRef40
Karen Nuytemans, Jessie Theuns, Marc Cruts, Christine Van Broeckhoven. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Human Mutation 31:7, 763-780
CrossRef41
Soraya Bardien, Angelica Marsberg, Rowena Keyser, Debbie Lombard, Suzanne Lesage, Alexis Brice, Jonathan Carr. (2010) LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson’s disease patients. Journal of Neural Transmission 117:7, 847-853
CrossRef42
Johanna Eerola, Petri T. Luoma, Terhi Peuralinna, Sonja Scholz, Coro Paisan-Ruiz, Anu Suomalainen, Andrew B. Singleton, Pentti J. Tienari. (2010) POLG1 polyglutamine tract variants associated with Parkinson's disease. Neuroscience Letters 477:1, 1-5
CrossRef43
S. Lesage, E. Patin, C. Condroyer, A. L. Leutenegger, E. Lohmann, N. Giladi, A. Bar-Shira, S. Belarbi, N. Hecham, P. Pollak, A. M. Ouvrard-Hernandez, S. Bardien, J. Carr, T. Benhassine, H. Tomiyama, C. Pirkevi, T. Hamadouche, C. Cazeneuve, A. N. Basak, N. Hattori, A. Durr, M. Tazir, A. Orr-Urtreger, L. Quintana-Murci, A. Brice, . (2010) Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Human Molecular Genetics 19:10, 1998-2004
CrossRef44
L. Correia Guedes, J.J. Ferreira, M.M. Rosa, M. Coelho, V. Bonifati, C. Sampaio. (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. Parkinsonism & Related Disorders 16:4, 237-242
CrossRef45
Won-Gi Seol. (2010) Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Reports 43:4, 233-244
CrossRef46
Jong-Min Kim, Jee-Young Lee, Hee Jin Kim, Ji Seon Kim, Eun-Soon Shin, Jin-Hwan Cho, Sung Sup Park, Beom S. Jeon. (2010) The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. Parkinsonism & Related Disorders 16:2, 85-88
CrossRef47
Marie Westerlund, Barry Hoffer, Lars Olson. (2010) Parkinson's disease: Exit toxins, enter genetics. Progress in Neurobiology 90:2, 146-156
CrossRef48
Sun Ju Chung. (2010) Genetics in Parkinson's disease. Journal of the Korean Medical Association 54:1, 70
CrossRef49
Stanley Fahn. (2010) Parkinson's disease: 10 years of progress, 1997-2007. Movement Disorders 25:S1, S2-S14
CrossRef50
Stephan Klebe, Sandra Thier, Delia Lorenz, Michael Nothnagel, Stefan Schreiber, Christine Klein, Johann Hagenah, Meike Kasten, Daniela Berg, Karin Srulijes, Thomas Gasser, Günther Deuschl, Gregor Kuhlenbäumer. (2010) LINGO1 is not associated with Parkinson's disease in German patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 9999B, n/a-n/a
CrossRef51
S. Lesage, A. Brice. (2010) Basi molecolari del morbo di Parkinson. EMC - Neurologia 10:2, 1-9
CrossRef52
Georgia Xiromerisiou, Efthimios Dardiotis, Vaïa Tsimourtou, Persa Maria Kountra, Konstantinos N. Paterakis, Eftychia Z. Kapsalaki, Kostas N. Fountas, Georgios M. Hadjigeorgiou. (2010) Genetic basis of Parkinson disease. Neurosurgical FOCUS 28:1, E7
CrossRef53
William Dauer, Cherry Cheng-Ying Ho. (2010) The biology and pathology of the familial Parkinson's disease protein LRRK2. Movement Disorders 25:S1, S40-S43
CrossRef54
Christian Wider, Tatiana Foroud, Zbigniew K. Wszolek. (2010) Clinical implications of gene discovery in Parkinson's disease and parkinsonism. Movement Disorders 25:S1, S15-S20
CrossRef55
Caroline Pirkevi, Suzanne Lesage, Alexis Brice, A. Nazli Başak. (2009) From Genes to Proteins in Mendelian Parkinson's Disease: An Overview. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 292:12, 1893-1901
CrossRef56
Taku Hatano, Shin-ichiro Kubo, Shigeto Sato, Nobutaka Hattori. (2009) Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease. Journal of Neurochemistry 111:5, 1075-1093
CrossRef57
Kristoffer Haugarvoll, Zbigniew K. Wszolek. (2009) Clinical features of LRRK2 parkinsonism. Parkinsonism & Related Disorders 15, S205-S208
CrossRef58
Avner Thaler, Elissa Ash, Ziv Gan-Or, Avi Orr-Urtreger, Nir Giladi. (2009) The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews. Journal of Neural Transmission 116:11, 1473-1482
CrossRef59
Udhaya Kumari, E. K. Tan. (2009) LRRK2 in Parkinsonâs disease: genetic and clinical studies from patients. FEBS Journal 276:22, 6455-6463
CrossRef60
Zijuan Zhang, Jean-Marc Burgunder, Xingkai An, Yan Wu, Wenjun Chen, Jinhong Zhang, Yingcheng Wang, Yanming Xu, Yingru Gou, Guanggu Yuan, Xueye Mao, Rong Peng. (2009) LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Movement Disorders 24:13, 1902-1905
CrossRef61
Ignacio F. Mata, Carolyn M. Hutter, María C. González-Fernández, Marian M. Pancorbo, Elena Lezcano, Cecilia Huerta, Marta Blazquez, Renee Ribacoba, Luis M. Guisasola, Carlos Salvador, Juan C. Gómez-Esteban, Juan J. Zarranz, Jon Infante, Joseph Jankovic, Hao Deng, Karen L. Edwards, Victoria Alvarez, Cyrus P. Zabetian. (2009) Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain. neurogenetics 10:4, 347-353
CrossRef62
Ariel B. Lindner, Alice Demarez. (2009) Protein aggregation as a paradigm of aging. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:10, 980-996
CrossRef63
Anat Bar-Shira, Carolyn M. Hutter, Nir Giladi, Cyrus P. Zabetian, Avi Orr-Urtreger. (2009) Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. neurogenetics 10:4, 355-358
CrossRef64
W. Sieh, Y. Choi, N. H. Chapman, U.-K. Craig, E. J. Steinbart, J. H. Rothstein, K. Oyanagi, R. M. Garruto, T. D. Bird, D. R. Galasko, G. D. Schellenberg, E. M. Wijsman. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Human Molecular Genetics 18:19, 3725-3738
CrossRef65
Saurabh Sen, Andrew B. West. (2009) The Therapeutic Potential of LRRK2 and α-Synuclein in Parkinson's Disease. Antioxidants & Redox Signaling 11:9, 2167-2187
CrossRef66
L. Gao, P. Gómez-Garre, F. J. Díaz-Corrales, F. Carrillo, M. Carballo, A. Palomino, J. Díaz-Martín, R. Mejías, P. J. Vime, J. López-Barneo, P. Mir. (2009) Prevalence and clinical features of LRRK2 mutations in patients with Parkinson’s disease in southern Spain. European Journal of Neurology 16:8, 957-960
CrossRef67
Coro Paisán-Ruiz. (2009) LRRK2 gene variation and its contribution to Parkinson disease. Human Mutation 30:8, 1153-1160
CrossRef68
Philippe Damier. (2009) Drug-induced dyskinesias. Current Opinion in Neurology 22:4, 394-399
CrossRef69
Thomas Gasser. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Reviews in Molecular Medicine 11,
CrossRef70
C. Pirkevi, S. Lesage, C. Condroyer, H. Tomiyama, N. Hattori, S. Ertan, A. Brice, A. N. Başak. (2009) A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype. neurogenetics 10:3, 271-273
CrossRef71
Karen Nuytemans, Bram Meeus, David Crosiers, Nathalie Brouwers, Dirk Goossens, Sebastiaan Engelborghs, Philippe Pals, Barbara Pickut, Marleen Van den Broeck, Ellen Corsmit, Patrick Cras, Peter P. De Deyn, Jurgen Del-Favero, Christine Van Broeckhoven, Jessie Theuns. (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Human Mutation 30:7, 1054-1061
CrossRef72
Ignacio F. Mata, Carlos Cosentino, Victoria Marca, Luis Torres, Pilar Mazzetti, Olimpio Ortega, Victor Raggio, Ruth Aljanati, Ricardo Buzó, Dora Yearout, Elena Dieguez, Cyrus P. Zabetian. (2009) LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism & Related Disorders 15:5, 370-373
CrossRef73
Cyrus P. Zabetian, Mitsutoshi Yamamoto, Alexis N. Lopez, Hiroshi Ujike, Ignacio F. Mata, Yuishin Izumi, Ryuji Kaji, Hirofumi Maruyama, Hiroyuki Morino, Masaya Oda, Carolyn M. Hutter, Karen L. Edwards, Gerard D. Schellenberg, Debby W. Tsuang, Dora Yearout, Eric B. Larson, Hideshi Kawakami. (2009) LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Movement Disorders 24:7, 1034-1041
CrossRef74
Christian Johannes Gloeckner, Annette Schumacher, Karsten Boldt, Marius Ueffing. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. Journal of Neurochemistry 109:4, 959-968
CrossRef75
Payal N. Gandhi, Shu G. Chen, Amy L. Wilson-Delfosse. (2009) Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease. Journal of Neuroscience Research 87:6, 1283-1295
CrossRef76
S. Lesage, A. Brice. (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics 18:R1, R48-R59
CrossRef77
Sharon Hassin-Baer, Yael Laitman, Esther Azizi, Irena Molchadski, Gilli Galore-Haskel, Frida Barak, Oren S. Cohen, Eitan Friedman. (2009) The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Journal of Neurology 256:3, 483-487
CrossRef78
Douglas W. Ethell, Qingyan Fei. (2009) Parkinson-Linked Genes and Toxins That Affect Neuronal Cell Death Through the Bcl-2 Family. Antioxidants & Redox Signaling 11:3, 529-540
CrossRef79
Gabriel Santpere, Isidre Ferrer. (2009) LRRK2 and neurodegeneration. Acta Neuropathologica 117:3, 227-246
CrossRef80
Knud Larsen, Lone Bruhn Madsen. (2009) Sequence conservation between porcine and human LRRK2. Molecular Biology Reports 36:2, 237-243
CrossRef81
Simon Cronin, Barbara Tomik, Daniel G Bradley, Agnieszka Slowik, Orla Hardiman. (2009) Screening for replication of genome-wide SNP associations in sporadic ALS. European Journal of Human Genetics 17:2, 213-218
CrossRef82
George D. Mellick, Gerhard A. Siebert, Manabu Funayama, Daniel D. Buchanan, Yuanzhe Li, Yoko Imamichi, Hiroyo Yoshino, Peter A. Silburn, Nobutaka Hattori. (2009) Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism & Related Disorders 15:2, 105-109
CrossRef83
Jason P. Covy, Wuxing Yuan, Elisa A. Waxman, Howard I. Hurtig, Vivianna M. Van Deerlin, Benoit I. Giasson. (2009) Clinical and pathological characteristics of patients with Leucine-rich repeat kinase-2 mutations. Movement Disorders 24:1, 32-39
CrossRef84
Jin-Whan Cho, Sung-Yeon Kim, Sung-Sup Park, Beom S. Jeon. (2009) The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy. Journal of Clinical Neurology 5:1, 29
CrossRef85
Jason P. Covy, Benoit I. Giasson. (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochemical and Biophysical Research Communications 378:3, 473-477
CrossRef86
Hiroyuki Tomiyama, Ikuko Mizuta, Yuanzhe Li, Manabu Funayama, Hiroyo Yoshino, Lin Li, Miho Murata, Mitsutoshi Yamamoto, Shin-ichiro Kubo, Yoshikuni Mizuno, Tatsushi Toda, Nobutaka Hattori. (2008) LRRK2 P755L variant in sporadic Parkinson’s disease. Journal of Human Genetics 53:11-12, 1012-1015
CrossRef87
Kenneth Marek, Danna Jennings, Gilles Tamagnan, John Seibyl. (2008) Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression. Annals of Neurology 64:S2, S111-S121
CrossRef88
Jose Bras, Andrew Singleton, Mark R. Cookson, John Hardy. (2008) Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS Journal 275:23, 5767-5773
CrossRef89
Heather Melrose. (2008) Update on the functional biology of Lrrk2. Future Neurology 3:6, 669-681
CrossRef90
Baek-Soo Han, Lorraine Iacovitti, Taku Katano, Nobutaka Hattori, Wongi Seol, Kwang-Soo Kim. (2008) Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neuroscience Letters 442:3, 190-194
CrossRef91
Spiridon Papapetropoulos, Nikhil Adi, Lina Shehadeh, Nanette Bishopric, Carlos Singer, Andreas A Argyriou, Elizabeth Chroni. (2008) Is the G2019S LRRK2 mutation common in all southern European populations?. Journal of Clinical Neuroscience 15:9, 1027-1030
CrossRef92
Nathalie Change, Géraldine Mercier, Gérard Lucotte. (2008) Genetic Screening of the G2019S Mutation of the LRRK2 Gene in Southwest European, North African, and Sephardic Jewish Subjects. Genetic Testing 12:3, 333-339
CrossRef93
Jörg B. Schulz. (2008) Update on the pathogenesis of Parkinson’s disease. Journal of Neurology 255:S5, 3-7
CrossRef94
Hani T.S. Benamer, Rajith de Silva, Khurram A. Siddiqui, Donald G. Grosset. (2008) Parkinson's disease in Arabs: A systematic review. Movement Disorders 23:9, 1205-1210
CrossRef95
Darren J. Moore. (2008) The biology and pathobiology of LRRK2: Implications for Parkinson's disease. Parkinsonism & Related Disorders 14, S92-S98
CrossRef96
Daniel G Healy, Mario Falchi, Sean S O'Sullivan, Vincenzo Bonifati, Alexandra Durr, Susan Bressman, Alexis Brice, Jan Aasly, Cyrus P Zabetian, Stefano Goldwurm, Joaquim J Ferreira, Eduardo Tolosa, Denise M Kay, Christine Klein, David R Williams, Connie Marras, Anthony E Lang, Zbigniew K Wszolek, Jose Berciano, Anthony HV Schapira, Timothy Lynch, Kailash P Bhatia, Thomas Gasser, Andrew J Lees, Nicholas W Wood. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. The Lancet Neurology 7:7, 583-590
CrossRef97
Chin-Song Lu, Hsiu-Chen Chang, Yi-Hsin Weng, Rou-Shayn Chen, Vincenzo Bonifati, Yah-Huei Wu-Chou. (2008) Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in Taiwan. Parkinsonism & Related Disorders 14:5, 393-396
CrossRef98
Yi Wei Lu, Eng‐King Tan. (2008) Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. Journal of Neuroscience Research 86:9, 1895-1901
CrossRef99
Carola Schiesling, Nicole Kieper, Kay Seidel, Rejko Krüger. (2008) Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathology and Applied Neurobiology 34:3, 255-271
CrossRef100
Eng-King Tan, Hui-Qin Lim, Yih Yuen, Yi Zhao. (2008) Pathogenicity of LRRK2 P755L variant in Parkinson's disease. Movement Disorders 23:5, 734-736
CrossRef101
Corinne Lautier, Stefano Goldwurm, Alexandra Dürr, Barbara Giovannone, William G. Tsiaras, Gianni Pezzoli, Alexis Brice, Robert J. Smith. (2008) Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease. The American Journal of Human Genetics 82:4, 822-833
CrossRef102
Njideka U. Okubadejo. (2008) An analysis of genetic studies of Parkinson's disease in Africa. Parkinsonism & Related Disorders 14:3, 177-182
CrossRef103
Márcia Mattos Gonçalves Pimentel, Karla Cristina Vasconcelos Moura, Cláudia Bueno Abdalla, João Santos Pereira, Ana Lúcia Zuma de Rosso, Denise Hack Nicaretta, Mário Campos Junior, Richard Morais de Almeida, Jussara Mendonça dos Santos, Izabel Cristina Constantino Bastos. (2008) A study of LRRK2 mutations and Parkinson's disease in Brazil. Neuroscience Letters 433:1, 17-21
CrossRef104
X.-K. An, R. Peng, T. Li, J.-M. Burgunder, Y. Wu, W.-J. Chen, J.-H. Zhang, Y.-C. Wang, Y.-M. Xu, Y.-R. Gou, G.-G. Yuan, Z.-J. Zhang. (2008) LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China. European Journal of Neurology 15:3, 301-305
CrossRef105
E. K. Tan, A. H. Schapira. (2008) Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. European Journal of Neurology 15:3, 203-204
CrossRef106
Renato P. Munhoz, Yosuke Wakutani, Connie Marras, Helio A. Teive, Salmo Raskin, Lineu C. Werneck, Danielle Moreno, Christine Sato, Anthony E. Lang, Ekaterina Rogaeva. (2008) The G2019SLRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. Movement Disorders 23:2, 290-294
CrossRef107
Benoit I. Giasson, Vivianna M. Van Deerlin. (2008) Mutations in <i>LRRK2</i> as a Cause of Parkinson’s Disease. Neurosignals 16:1, 99-105
CrossRef108
Serena Rosner, Nir Giladi, Avi Orr-Urtreger. (2008) Advances in the genetics of Parkinson's disease. Acta Pharmacologica Sinica 29:1, 21-34
CrossRef109
María C. González-Fernández, Elena Lezcano, Owen A. Ross, Juan C. Gómez-Esteban, Fernando Gómez-Busto, Fernando Velasco, Maite Alvarez-Alvarez, María B. Rodríguez-Martínez, Roberto Ciordia, Juan J. Zarranz, Matthew J. Farrer, Ignacio F. Mata, Marian M. de Pancorbo. (2007) Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism & Related Disorders 13:8, 509-515
CrossRef110
Elisa Greggio, Andrew Singleton. (2007) Kinase signaling pathways as potential targets in the treatment of Parkinson’s disease. Expert Review of Proteomics 4:6, 783-792
CrossRef111
Nathan Pankratz, Tatiana Foroud. (2007) Genetics of Parkinson disease. Genetics in Medicine 9:12, 801-811
CrossRef112
Susan Winkler, Inke R König, Katja Lohmann-Hedrich, Peter Vieregge, Vladimir Kostic, Christine Klein. (2007) Role of ethnicity on the association of MAPT H1 haplotypes and subhaplotypes in Parkinson's disease. European Journal of Human Genetics 15:11, 1163-1168
CrossRef113
E-K Tan. (2007) The role of common genetic risk variants in Parkinson disease. Clinical Genetics 72:5, 387-393
CrossRef114
K. Kalinderi, L. Fidani, S. Bostantjopoulou, Z. Katsarou, A. Kotsis. (2007) The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. European Journal of Neurology 14:10, 1088-1090
CrossRef115
Vincenzo Bonifati. (2007) LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg)—Linking Familial and Sporadic Parkinson’s Disease. Neurochemical Research 32:10, 1700-1708
CrossRef116
Eng-King Tan, Yi Zhao, Louis Tan, Hui-Qin Lim, Jasinda Lee, Yih Yuen, Ratnagopal Pavanni, Meng-Cheong Wong, Stephanie Fook-Chong, Jian-Jun Liu. (2007) Analysis ofLRRK2 Gly2385Arg genetic variant in non-Chinese Asians. Movement Disorders 22:12, 1816-1818
CrossRef117
Dietrich Haubenberger, Silvia Bonelli, Christoph Hotzy, Petra Leitner, Peter Lichtner, Doris Samal, Regina Katzenschlager, Atbin Djamshidian, Thomas Brücke, Michaela Steffelbauer, Christian Bancher, Josef Grossmann, Gerhard Ransmayr, Tim M. Strom, Thomas Meitinger, Thomas Gasser, Eduard Auff, Alexander Zimprich. (2007) A novelLRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Movement Disorders 22:11, 1640-1643
CrossRef118
Christine Klein, Katja Lohmann-Hedrich. (2007) Impact of recent genetic findings in Parkinson??s disease. Current Opinion in Neurology 20:4, 453-464
CrossRef119
C PEREZPASTENE, S COBB, F DIAZGREZ, M HULIHAN, M MIRANDA, P VENEGAS, O GODOY, J KACHERGUS, O ROSS, L LAYSON. (2007) Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. Neuroscience Letters 422:3, 193-197
CrossRef120
M. J. Hurley, P. H. Patel, M. J. Jackson, L. A. Smith, S. Rose, P. Jenner. (2007) Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with l-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. European Journal of Neuroscience 26:1, 171-177
CrossRef121
Eng-King Tan, Lisa M. Skipper. (2007) Pathogenic mutations in Parkinson disease. Human Mutation 28:7, 641-653
CrossRef122
Enza Maria Valente, Alessandro Ferraris. (2007) Heterozygous mutations in genes causing parkinsonism: monogenic disorders go complex. The Lancet Neurology 6:7, 576-578
CrossRef123
Christine Klein, Katja Lohmann-Hedrich, Ekaterina Rogaeva, Michael G Schlossmacher, Anthony E Lang. (2007) Deciphering the role of heterozygous mutations in genes associated with parkinsonism. The Lancet Neurology 6:7, 652-662
CrossRef124
Joaquim J. Ferreira, Leonor Correia Guedes, Mário Miguel Rosa, Miguel Coelho, Marina van Doeselaar, Dorothea Schweiger, Alessio Di Fonzo, Ben A. Oostra, Cristina Sampaio, Vincenzo Bonifati. (2007) High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Movement Disorders 22:8, 1194-1201
CrossRef125
Huw R Morris. (2007) Autosomal dominant Parkinson’s disease and the route to new therapies. Expert Review of Neurotherapeutics 7:6, 649-656
CrossRef126
Shira G. Ziegler, Michael J. Eblan, Usha Gutti, Kathleen S. Hruska, Barbara K. Stubblefield, Ozlem Goker-Alpan, Mary E. LaMarca, Ellen Sidransky. (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molecular Genetics and Metabolism 91:2, 195-200
CrossRef127
Sung Bae Lee, Wonho Kim, Sungkyu Lee, Jongkyeong Chung. (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochemical and Biophysical Research Communications 358:2, 534-539
CrossRef128
H DENG, W LE, M HUANG, W XIE, T PAN, J JANKOVIC. (2007) Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neuroscience Letters 419:2, 104-107
CrossRef129
M. Toft, K. Haugarvoll, O. A. Ross, M. J. Farrer, J. O. Aasly. (2007) LRRK2 and Parkinson?s disease in Norway. Acta Neurologica Scandinavica 115:s187, 72-75
CrossRef130
D Civitelli, P Tarantino, G Nicoletti, IC Cirò Candiano, F Annesi, EV De Marco, S Carrideo, FE Rocca, F Condino, P Spadafora, P Pugliese, S D’Asero, M Morelli, S Paglionico, G Annesi, A Quattrone. (2007) LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson’s disease. Clinical Genetics 71:4, 367-370
CrossRef131
S. N. Illarioshkin, M. I. Shadrina, P. A. Slominsky, E. V. Bespalova, T. B. Zagorovskaya, G. Kh. Bagyeva, E. D. Markova, S. A. Limborska, I. A. Ivanova-Smolenskaya. (2007) A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. European Journal of Neurology 14:4, 413-417
CrossRef132
Pedro Gonzalez-Alegre. (2007) Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacology & Therapeutics 114:1, 34-55
CrossRef133
Laurie J. Ozelius, Tatiana Foroud, Susanne May, Geetha Senthil, Paola Sandroni, Phillip A. Low, Stephen Reich, Amy Colcher, Matthew B. Stern, William G. Ondo, Joseph Jankovic, Neng Huang, Caroline M. Tanner, Peter Novak, Sid Gilman, Frederick J. Marshall, G. Frederick Wooten, Thomas C. Chelimsky, Clifford W. Shults, . (2007) G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Movement Disorders 22:4, 546-549
CrossRef134
Matthew J. Farrer, Jeremy T. Stone, Chin-Hsien Lin, Justus C. Dächsel, Mary M. Hulihan, Kristoffer Haugarvoll, Owen A. Ross, Ruey-Meei Wu. (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism & Related Disorders 13:2, 89-92
CrossRef135
Tiziana Squillaro, Franca Cambi, Giuseppe Ciacci, Simone Rossi, Monica Ulivelli, Alessandro Malandrini, Maria Antonietta Mencarelli, Francesca Mari, Alessandra Renieri, Francesca Ariani. (2007) Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease. Journal of Human Genetics 52:3, 201-204
CrossRef136
Giovanni Cossu, Marina van Doeselaar, Marcello Deriu, Maurizio Melis, Andrea Molari, Alessio Di Fonzo, Ben A. Oostra, Vincenzo Bonifati. (2007) LRRK2 mutations and Parkinson's disease in Sardinia—A Mediterranean genetic isolate. Parkinsonism & Related Disorders 13:1, 17-21
CrossRef137
Manabu Funayama, Yuanzhe Li, Hiroyuki Tomiyama, Hiroyo Yoshino, Yoko Imamichi, Mitsutoshi Yamamoto, Miho Murata, Tatsushi Toda, Yoshikuni Mizuno, Nobutaka Hattori. (2007) Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. NeuroReport 18:3, 273-275
CrossRef138
Norra MacReady. (2007) Noteworthy Advances in Movement Disorders. Neurology Today 7:4, 4-5
CrossRef139
E. K. Tan, Y. Zhao, L. Skipper, M. G. Tan, A. Di Fonzo, L. Sun, S. Fook-Chong, S. Tang, E. Chua, Y. Yuen, L. Tan, R. Pavanni, M. C. Wong, P. Kolatkar, C. S. Lu, V. Bonifati, J. J. Liu. (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence. Human Genetics 120:6, 857-863
CrossRef140
Maria Teresa Giordana, Carla D'Agostino, Giovanni Albani, Alessandro Mauro, Alessio Di Fonzo, Angelo Antonini, Vincenzo Bonifati. (2007) Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation. Movement Disorders 22:2, 275-278
CrossRef141
Suzanne Lesage, Laurence Leclere, Ebba Lohmann, Michel Borg, Merle Ruberg, Alexandra Dürr, Alexis Brice. (2007) Frequency of the <i>LRRK2 </i>G2019S Mutation in Siblings with Parkinson’s Disease. Neurodegenerative Diseases 4:2-3, 195-198
CrossRef142
Joseph Jankovic. 2007. Movement Disorders. , 735-763.
CrossRef143
Lianna Ishihara, Rachel A. Gibson, Liling Warren, Rim Amouri, Kelly Lyons, Catherine Wielinski, Christine Hunter, Jina E. Swartz, Ramu Elango, P. Anthony Akkari, David Leppert, Linda Surh, Kevin H. Reeves, Siwan Thomas, Leigh Ragone, Nobutaka Hattori, Rajesh Pahwa, Joseph Jankovic, Martha Nance, Alan Freeman, Neziha Gouider-Khouja, Mounir Kefi, Mourad Zouari, Samia Ben Sassi, Samia Ben Yahmed, Ghada El Euch-Fayeche, Lefkos Middleton, David J. Burn, Ray L. Watts, Faycal Hentati. (2007) Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Movement Disorders 22:1, 55-61
CrossRef144
Thomas Gasser. (2007) Update on the genetics of Parkinson's disease. Movement Disorders 22:S17, S343-S350
CrossRef145
Robert E Burke. (2007) Kinase signaling pathways: potential therapeutic targets in Parkinson’s disease. Future Neurology 2:1, 39-49
CrossRef146
Michael Schüpbach, Ebba Lohmann, Mathieu Anheim, Suzanne Lesage, Virginie Czernecki, Sadek Yaici, Yulia Worbe, Perrine Charles, Marie-Laure Welter, Pierre Pollak, Alexandra Dürr, Yves Agid, Alexis Brice. (2007) Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Movement Disorders 22:1, 119-122
CrossRef147
Eng-King Tan, Lisa Skipper, Louis Tan, Jian-Jun Liu. (2007) LRRK2 G2019S founder haplotype in the Chinese population. Movement Disorders 22:1, 105-107
CrossRef148
Vincenzo Bonifati. (2007) Genetics of parkinsonism. Parkinsonism & Related Disorders 13, S233-S241
CrossRef149
Shinji Higashi, Darren J. Moore, Rebecca E. Colebrooke, Saskia Biskup, Valina L. Dawson, Heii Arai, Ted M. Dawson, Piers C. Emson. (2007) Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry 100:2, 368-381
CrossRef150
Eduardo Tolosa. (2007) Movement disorders: advances on many fronts. The Lancet Neurology 6:1, 7-8
CrossRef151
Justus C. Dächsel, Ignacio F. Mata, Owen A. Ross, Julie P. Taylor, Sarah J. Lincoln, Kelly M. Hinkle, Cecilia Huerta, Renee Ribacoba, Marta Blazquez, Victoria Alvarez. (2006) Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2. Neuroscience Letters 410:2, 80-84
CrossRef152
Hao Deng, WeiDong Le, Yi Guo, Christine B. Hunter, WenJie Xie, MaoSheng Huang, Joseph Jankovic. (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. Journal of the Neurological Sciences 251:1-2, 102-106
CrossRef153
Sofya N. Pchelina, Andrei F. Yakimovskii, Olga N. Ivanova, Anton K. Emelianov, Andrei H. Zakharchuk, Alexander L. Schwarzman. (2006) G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia. Movement Disorders 21:12, 2234-2236
CrossRef154
Sohan Punia, Madhuri Behari, Shyla T. Govindappa, Pazhayannur V. Swaminath, Sachi Jayaram, Vinay Goyal, Uday B. Muthane, R.C. Juyal, B.K. Thelma. (2006) Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neuroscience Letters 409:2, 83-88
CrossRef155
Asa Abeliovich, M. Flint Beal. (2006) Parkinsonism genes: culprits and clues. Journal of Neurochemistry 99:4, 1062-1072
CrossRef156
A. Wood-Kaczmar, S. Gandhi, N.W. Wood. (2006) Understanding the molecular causes of Parkinson's disease. Trends in Molecular Medicine 12:11, 521-528
CrossRef157
Hao Deng, WeiDong Le, Anthony L. Davidson, WenJie Xie, Joseph Jankovic. (2006) The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neuroscience Letters 407:2, 97-100
CrossRef158
John Hardy, Huaiban Cai, Mark R. Cookson, Katrina Gwinn-Hardy, Andrew Singleton. (2006) Genetics of Parkinson's disease and parkinsonism. Annals of Neurology 60:4, 389-398
CrossRef159
Stefano Goldwurm, Michela Zini, Alessio Di Fonzo, Danilo De Gaspari, Chiara Siri, Erik J. Simons, Marina van Doeselaar, Silvana Tesei, Angelo Antonini, Margherita Canesi, Anna Zecchinelli, Claudio Mariani, Nicoletta Meucci, Giorgio Sacilotto, Roberto Cilia, Ioannis U. Isaias, A. Bonetti, Francesca Sironi, Sara Ricca, Ben A. Oostra, Vincenzo Bonifati, Gianni Pezzoli. (2006) LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism & Related Disorders 12:7, 410-419
CrossRef160
Cyrus P. Zabetian, Carolyn M. Hutter, Dora Yearout, Alexis N. Lopez, Stewart A. Factor, Alida Griffith, Berta C. Leis, Thomas D. Bird, John G. Nutt, Donald S. Higgins, John W. Roberts, Denise M. Kay, Karen L. Edwards, Ali Samii, Haydeh Payami. (2006) LRRK2 G2019S in Families with Parkinson Disease Who Originated from Europe and the Middle East: Evidence of Two Distinct Founding Events Beginning Two Millennia Ago. The American Journal of Human Genetics 79:4, 752-758
CrossRef161
Yonghong Li, Steven Schrodi, Charles Rowland, Kristina Tacey, Joseph Catanese, Andrew Grupe. (2006) Genetic evidence for ubiquitin-specific proteases USP24 and USP40 as candidate genes for late-onset Parkinson disease. Human Mutation 27:10, 1017-1023
CrossRef162
Vincenzo Bonifati. (2006) Parkinson's Disease: The LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. European Journal of Human Genetics 14:10, 1061-1062
CrossRef163
Jacobo Lester, Enrique Otero-Siliceo. (2006) Parkinson??s Disease and Genetics. The Neurologist 12:5, 240-244
CrossRef164
Katja Hedrich, Susen Winkler, Johann Hagenah, Kemal Kabakci, Meike Kasten, Eberhard Schwinger, Jens Volkmann, Peter P. Pramstaller, Vladimir Kostic, Peter Vieregge, Christine Klein. (2006) RecurrentLRRK2 (Park8) mutations in early-onset Parkinson's disease. Movement Disorders 21:9, 1506-1510
CrossRef165
Denise M. Kay, Tom D. Bird, Cyrus P. Zabetian, Stewart A. Factor, Ali Samii, Donald S. Higgins, John Nutt, John W. Roberts, Alida Griffith, Berta C. Leis, Jennifer S. Montimurro, Sean Philpott, Haydeh Payami. (2006) Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease. Genetic Testing 10:3, 221-227
CrossRef166
M EBLAN, S SCHOLZ, B STUBBLEFIELD, U GUTTI, O GOKERALPAN, K HRUSKA, A SINGLETON, E SIDRANSKY. (2006) Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neuroscience Letters 404:1-2, 163-165
CrossRef167
Kristoffer Haugarvoll, Zbigniew K. Wszolek. (2006) PARK8 LRRK2 parkinsonism. Current Neurology and Neuroscience Reports 6:4, 287-294
CrossRef168
Alessio Fonzo, Yah-Huei Wu-Chou, Chin-Song Lu, Marina Doeselaar, Erik J. Simons, Christan F. Rohé, Hsiu-Chen Chang, Rou-Shayn Chen, Yi-Hsin Weng, Nicola Vanacore, Guido J. Breedveld, Ben A. Oostra, Vincenzo Bonifati. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan. Neurogenetics 7:3, 133-138
CrossRef169
E Ray Dorsey, Robert G Holloway, Bernard M Ravina. (2006) Biomarkers in Parkinson’s disease. Expert Review of Neurotherapeutics 6:6, 823-831
CrossRef170
Ignacio F. Mata, William J. Wedemeyer, Matthew J. Farrer, Julie P. Taylor, Kathleen A. Gallo. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neurosciences 29:5, 286-293
CrossRef171
Matthew James Farrer. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nature Reviews Genetics 7:4, 306-318
CrossRef172
Wendy R. Galpern, Anthony E. Lang. (2006) Interface between tauopathies and synucleinopathies: A tale of two proteins. Annals of Neurology 59:3, 449-458
CrossRef173
Christine Klein, Michael G Schlossmacher. (2006) The genetics of Parkinson disease: implications for neurological care. Nature Clinical Practice Neurology 2:3, 136-146
CrossRef174
Richard Robinson. (2006) GENE MUTATION IN ASHKENAZI JEWS AND NORTH AFRICAN ARABS IS LIKELY ‘GOLDMINE’ FOR PARKINSON RESEARCH. Neurology 6:4, 7-9
CrossRef175
Ozelius, Laurie J., Senthil, Geetha, , Saunders-Pullman, Rachel, Ohmann, Erin, Deligtisch, Amanda, Tagliati, Michele, Hunt, Ann L., , Klein, Christine, , Henick, Brian, Hailpern, Susan M., Lipton, Richard B., , Soto-Valencia, Jeannie, , Risch, Neil, , Bressman, Susan B., . (2006) LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews. New England Journal of Medicine 354:4, 424-425
Full Text176
Vincenzo Bonifati. (2006) The pleomorphic pathology of inherited parkinson’s disease: Lessons from LRRK2. Current Neurology and Neuroscience Reports 6:5, 355-357
CrossRef177
Anne Messer, Julie McLear. (2006) The Therapeutic Potential of Intrabodies in Neurologic Disorders. BioDrugs 20:6, 327-333
CrossRef178
Chong Sik Lee, Sun Ju Chung, Jae Seung Kim. (2006) Syndromic Approach to Parkinson's Disease: Role of Functional Imaging. Journal of Clinical Neurology 2:2, 83
CrossRef
